This approach demonstrated the improved anti-tumour efficacy of PD-1-silenced, MSLN-targeted CAR-T cells across multiple cancer models and underscores the therapeutic potential of targeting immune checkpoints like PD-1 to boost CAR T cell therapies against various tumours [172,173]. Here, MSLN is linked to neoplasm.